3‘-Phosphoadenosine-5‘-phosphosulfate Reductase in Complex with Thioredoxin: A Structural Snapshot in the Catalytic Cycle by Chartron, Justin et al.
3′-Phosphoadenosine-5′-phosphosulfate Reductase in Complex
with Thioredoxin: A Structural Snapshot in the Catalytic Cycle,†,‡
Justin Chartron§,||, Carrie Shiau⊥, C. David Stout§, and Kate S. Carroll*,@
Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037,
Department of Molecular and Cell Biology, University of California, Berkeley, California 94720,
and Department of Chemistry and The Life Sciences Institute, University of Michigan, Ann Arbor,
Michigan 48109
Abstract
The crystal structure of Escherichia coli 3′-phosphoadenosine-5′-phosphosulfate (PAPS) reductase
in complex with E. coli thioredoxin 1 (Trx1) has been determined to 3.0 Å resolution. The two
proteins are covalently linked via a mixed disulfide that forms during nucleophilic attack of Trx’s
N-terminal cysteine on the Sγ atom of the PAPS reductase S-sulfocysteine (E-Cys-Sγ-SO3−), a
central intermediate in the catalytic cycle. For the first time in a crystal structure, residues 235–
244 in the PAPS reductase C-terminus are observed, depicting an array of interprotein salt bridges
between Trx and the strictly conserved glutathione-like sequence,
Glu238Cys239Gly240Leu241His242. The structure also reveals a Trx-binding surface adjacent to the
active site cleft and regions of PAPS reductase associated with conformational change. Interaction
at this site strategically positions Trx to bind the S-sulfated C-terminus and addresses the
mechanism for requisite structural rearrangement of this domain. An apparent sulfite-binding
pocket at the protein–protein interface explicitly orients the S-sulfocysteine Sγ atom for
nucleophilic attack in a subsequent step. Taken together, the structure of PAPS reductase in
complex with Trx highlights the large structural rearrangement required to accomplish
sulfonucleotide reduction and suggests a role for Trx in catalysis beyond the paradigm of disulfide
reduction.
Sulfonucleotide reductases (SRs)1 catalyze the reduction of adenylated sulfate to sulfite, the
first committed step in the production of reduced sulfur that is required for de novo cysteine
biosynthesis in plants, fungi, and many bacteria (Figure 1A) (1, 2). The two classes of
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enzymes in this family are distinguished by substrate specificity and by the presence or
absence of an iron–sulfur cluster (3, 4). Adenosine-5′-phosphosulfate (APS) is reduced by
the [4Fe-4S]-containing enzyme APS reductase and is found in archae, Gram-positive
bacteria, and plants (Figure 1A) (4, 5). In contrast, 3′-phosphoadenosine-5′-phosphosulfate
(PAPS) is reduced by PAPS reductase, an enzyme that lacks the cluster and is present in
enteric bacteria and yeast (Figure 1A) (6, 7). The sequences of APS and PAPS reductases
are approximately 25–30% identical, and with the determination of the crystal structure of
Pseudomonas aeruginosa APS reductase, it is established that these enzymes are structurally
homologous (8, 9).
SRs are found in many human pathogens, such as Mycobacterium tuberculosis, which
accounts for 3 million deaths per year worldwide (10). In addition to lethal synergy with
HIV, this epidemic is also fueled by the increasing number of individuals infected with
multidrug resistant strains of M. tuberculosis, presently estimated at 50 million (11).
Identification of new targets and antibiotics is paramount to addressing this growing
problem (12, 13). In M. tuberculosis, the SR belongs to the class of APS reducing enzymes
(3, 14) and the cysteine product of this metabolic pathway can be transformed into
methionine, essential cofactors such as coenzyme A, biotin, thiamine, and the antioxidant
mycothiol (the mycobacterial equivalent of glutathione) (15). APS reductase was identified
in a screen for essential genes in Mycobacterium bovis BCG (16), and recently, it has also
been demonstrated that APS reductase activity is required for the survival of M. tuberculosis
during the persistence phase of infection in a murine model of tuberculosis (17). Parallel
studies of APS and PAPS reductase enzymes address the general mechanism of
sulfonucleotide reduction (3) (see details below), consistent with their structural homology
(8, 9). In particular, PAPS reductase is an attractive model for investigating general features
of sulfonucleotide reduction due to the absence of an oxygen sensitive iron–sulfur cluster.
Additionally, PAPS reductase and sulfate-dependent pathways are present in pathogens such
Escherichia coli, Salmonella typhimurium, and Yersinia pestis, providing further motivation
for study of this enzyme. Notably, SRs are not found in humans, further increasing their
interest as potential targets for therapeutic intervention.
The input of two electrons is required for sulfonucleotide reduction, and these can be
supplied by a protein cofactor with a redox-active disulfide bond, known as thioredoxin
(Trx) (18–20). Biochemical, spectroscopic, and mass spectrometry investigations of
sulfonucleotide reductases in both APS- and PAPS-dependent enzymes are consistent with a
two-step mechanism (Figure 1B), in which the sulfonucleotide undergoes nucleophilic
attack by an absolutely conserved cysteine to form an enzyme S-sulfocysteine intermediate,
E-Cys-Sγ-SO3− (previously termed “thiosulfonate intermediate”) (3, 8, 21, 22). In a
subsequent step, sulfite is released in a Trx-dependent reaction (3, 8, 21, 22). Hence, APS
and PAPS reductases perform the same overall chemistry to catalyze sulfonucleotide
reduction, despite their differences in substrate specificity (3). In a manner analogous to Trx
reduction of protein disulfide bonds, we have postulated that nucleophilic attack by Trx
takes place at the Sγ atom of the S-sulfocysteine intermediate (Figure 1B) (3). This reaction
would result in the formation of a mixed disulfide between Trx and the SR, concomitantly
releasing sulfite. Nonetheless, nucleophilic attack at the more highly oxidized sulfur atom is
also chemically plausible, and distinction between these models has awaited further
experimental examination.
In addition to the chemical transformations that are taking place, biochemical and structural
data are consistent with significant structural rearrangement during the SR catalytic cycle (3,
8). In particular, the 25 C-terminal residues of SRs (including the essential cysteine
nucleophile) are highly mobile (8, 9). Defining the molecular interactions of Trx with the S-
sulfated C-terminus and associated conformational rearrangements is, therefore, essential to
Chartron et al. Page 2
Biochemistry. Author manuscript; available in PMC 2011 June 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
elucidating the mechanism of sulfonucleotide reduction. Molecular interactions distal from
the C-terminal residues and the scissile S-sulfocysteine bond could also play a role in Trx–
enzyme recognition, and in addition to SRs (sulfur assimilation), Trx is involved in the
reduction of numerous other enzymes such as ribonucleotide reductase (DNA synthesis)
(23) and methionine sulfoxide reductase (protein repair) (18, 24). Gaining insight into the
molecular determinants that govern Trx–target recognition is therefore a question of
fundamental importance. Three-dimensional structural information obtained from Trx–
protein complexes, “caught” in the act of reduction, is a necessary step in addressing this
question. However, with the exception of barley Trx h isoform 2 (HvTrxh2) in complex with
α-amylase/subtilisin inhibitor (BASI) determined to 2.3 Å (25), no other structures of a
mixed disulfide intermediate with a full-length target protein have been described, and in
particular, structural insight into the complex that forms between Trx and an enzyme target
during its catalytic cycle has yet to be reported.
Here we describe the structure of E. coli PAPS reductase in complex with E. coli Trx1, a
key intermediate present during the catalytic cycle, at a resolution of 3.0 Å. The two proteins
are covalently linked via a mixed disulfide that forms during nucleophilic attack of Trx’s N-
terminal cysteine on the Sγ atom of the PAPS reductase S-sulfocysteine intermediate. For
the first time in a crystal structure, residues 235–244 of the C-terminus of PAPS reductase
are ordered, permitting analysis of the interactions between Trx and the strictly conserved
glutathione-like sequence, Glu238Cys239-Gly240Leu241His242. A second site of protein–
protein interaction is also observed near the PAPS reductase active site and adjacent to the
flexible C-terminal tail. Taken together, the structure of PAPS reductase in a mixed disulfide
complex with Trx provides a molecular rationale for interaction of these proteins,
illuminates the large conformational rearrangements required for sulfonucleotide reduction,
and reveals a unique protein–protein interface as a potential candidate for disruption by
small molecule or peptide inhibitors.
EXPERIMENTAL PROCEDURES
Cloning
Construction of the E. coli PAPS reductase pET24b (Novagen; contains a plasmid-encoded
C-terminal His tag) protein expression vector has been previously described (3). Trx1 was
amplified from E. coli genomic DNA ATC 700926 (ATCC) using the forward primer (5′-
gggcatatgatgagcgataaaat-3′) and the reverse primer (5′-ggggggatccttacgccaggttag-3′). PCR
mixtures contained each primer at 0.25 μM, 10 ng of genomic DNA template, and 2.5 units
of Pfu DNA polymerase in a reaction buffer supplied by the manufacturer. The PCR product
was ligated into a Zero Blunt Topo cloning vector (Invitrogen), digested with NdeI and
BamHI, and ligated to similarly cut pET14b (Novagen; contains a plasmid-encoded N-
terminal His tag). Construction of the P. aeruginosa APS reductase pET24b protein
expression vector has been described previously (3). The gene encoding P. aeruginosa Trx
was amplified from P. aeruginosa genomic DNA ATCC 47085D (ATCC) using the forward
primer (5′-ggggcatatgagcgaacatatcgtcaacg-3′) and the reverse primer (5′-
ggggcatatgagcgaacatatcgtcaacg-3′). The E. coli Trx1 and P. aeruginosa Trx Cys35Ala
variants were constructed using the Quikchange PCR mutagenesis kit (Stratagene) according
to the manufacturer’s specifications. Successful incorporation of the desired mutation was
confirmed by sequencing, and once it was verified, the plasmid was transformed into
BL21(DE3) (Novagen) for protein expression as described below.
Protein Purification
Plasmids containing E. coli PAPS reductase, P. aeruginosa APS reductase, or Trx were
transformed into BL21(DE3) cells, grown to an OD of 0.6 at 37 °C, and induced with 0.4
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mM IPTG. Cells were harvested after growth for 4 h at 30 °C (or 37 °C for Trx). His-tagged
PAPS reductase and Trx were purified using a previously established procedure via affinity
and size-exclusion chromatography (3). Briefly, after affinity chromatography, proteins
were incubated with 10 mM DTT at 37 °C for 15 min and concentrated, and DTT-free
protein was prepared by size-exclusion chromatography on a 10/30 Superdex 200 column
(GE Healthcare) equilibrated in gel filtration buffer [50 mM Tris-HCl (pH 8.0) with an ionic
strength of 150 mM with NaCl]. Desired fractions were collected, frozen in liquid nitrogen,
and stored at −80 °C.
Formation of the Sulfonucleotide Reductase–Trx Complex
For protein crystallography, PAPS reductase S-sulfocysteine intermediate was formed by
incubating PAPS reductase with 2-fold molar excess of PAPS substrate for 5–10 min at 37
°C. Quantitative formation of the PAPS reductase S-sulfocysteine intermediate was verified
by the expected shift in the molecular mass of PAPS reductase by 80 Da (the molecular
mass of a covalently bound sulfite) via electrospray mass spectrometry (3, 21).
Subsequently, the PAPS reductase S-sulfocysteine intermediate was incubated with a 2-fold
molar excess of Trx Cys35Ala for 5–10 min at 37 °C. For protein crystallography, size-
exclusion chromatography was employed to purify the resulting complex from excess Trx
Cys35Ala. For reversed phase HPLC and nonreducing SDS–PAGE analysis, PAPS
reductase and a 2-fold molar excess of PAPS substrate (or buffer only) were incubated as
described above. The final concentration of the PAPS reductase S-sulfocysteine intermediate
or PAPS reductase alone was varied from 0 to 25 μM, as reported in the figure legends.
Subsequently, Trx Cys35Ala was added to reaction mixtures at final concentrations of 1–10
μM. Complex formation was allowed to proceed for 20 s to 10 min at room temperature.
The reverse set of experiments was carried out by employing a constant amount of PAPS
reductase (1–10 μM) with increasing concentrations of Trx1 Cys35Ala (0–25 μM).
Reactions were quenched, and the extent of complex formation was quantified as described
below. Identical experiments were carried out for APS reductase and Trx Cys35Ala from P.
aeruginosa.
Reversed Phase HPLC
Reactions between the PAPS reductase S-sulfocysteine intermediate or PAPS reductase
alone and Trx1 Cys35Ala were quenched by the addition of 30 μL of 0.1% trifluoroacetic
acid (TFA). The low pH of the quench buffer protonates free thiols and inhibits formation of
the SR–Trx complex by preventing formation of the requisite thiolate. Reaction mixtures
were separated on a protein–peptide 218TP54 C18 column (Vydac) employing a gradient of
40 to 55% acetonitrile and 0.1% TFA over a period of 20 min. Protein peaks were collected
and their molecular masses determined by electrospray mass spectrometry.
Nonreducing SDS–PAGE
Reactions were quenched by the addition of iodoacetamide (25 mM), as described
previously (3). Addition of this reagent covalently modifies remaining unreacted free thiols
and, thus, prevents further disulfide formation during reactions and in subsequent sample
preparation steps (e.g., unfolding in nonreducing SDS–PAGE load dye and heating samples
prior to loading). Samples were separated on 12% Bis-Tris Criterion XT Precast Gels, and
protein was visualized by staining with Coomassie Blue or Sypro Orange (Invitrogen). For
Sypro Orange, gels were stained in the dark for 40 min and destained with 7.5% acetic acid
in the dark for 1 min. Reaction products were visualized on a Typhoon gel imaging system
(GE Healthcare) and quantified using Image Quant. The rate of formation of the PAPS
reductase–Trx Cys35Ala complex was plotted as a function of increasing Trx Cys35Ala or
PAPS reductase S-sulfocysteine intermediate concentration. Data were fit to the equation for
active site-directed irreversible inhibition (26) using Kaleidagraph (Synergy Software). The
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reaction of the inhibitor (Trx Cys35Ala) with the PAPS reductase S-sulfocysteine
intermediate involves the initial formation of a reversibly bound PAPS reductase S-
sulfocysteine–Trx complex followed by covalent modification (e.g., mixed disulfide
formation) and, thus, irreversible inhibition:
The scheme is analogous to the Michaelis–Menten mechanism, and the reaction exhibits
saturation kinetics with an increasing inhibitor concentration (26):
Kinetic data were obtained in at least two independent experiments, and the standard error
was less than 15%. Due to the limit of detection, the minimum practical protein
concentration used in these experiments was 0.5 μM, and therefore, the reported apparent Ki
represents an upper limit on the affinity between the PAPS reductase S-sulfocysteine
intermediate and Trx.
Crystallographic Analysis
Crystals were grown by vapor diffusion in sitting drops containing 2 μL of the E. coli PAPS
reductase–Trx Cys35Ala complex prepared as described above at 1.5 mg/mL in 50 mM Tris-
HCl (pH 8.0) with NaCl added to an ionic strength of 150 mM, and 2 μL of a reservoir
solution consisting of 10% (w/v) PEG3400 in 0.2 M KH2-PO4 (pH 4.6). Orthorhombic
crystals with dimensions of 200 μm × 30 μm × 20 μm grew at 18 °C over 3–4 weeks.
Crystals were briefly soaked in a cryoprotectant solution of 7% (w/v) PEG3400, 0.2 M
KH2PO4 (pH 4.6), and 20% (v/v) glycerol and flash-frozen in liquid N2. Forty-seven
crystals were evaluated at SSRL BL 1-5 using automated screening Blu-ice hutch control
software and subjected to in situ annealing between 100 K and room temperature for 4–10 s
intervals. One crystal annealed twice for 4 s displayed significant unit cell shrinkage and
anisotropic diffraction to 2.8 Å resolution; a complete data set was collected to 3.0 Å (Table
1).
The structure was determined by molecular replacement using Phaser (27) to locate the
PAPS reductase molecule and, subsequently, Molrep (28) to locate Trx. The search models
comprised residues 2–216 of E. coli PAPS reductase from an independently determined
structure (data not shown) homologous with PDB entry 1SUR (9) and E. coli Trx (PDB
entry 2TRX). Following rigid body refinement using Refmac (29), σA-weighted 2|Fo| − |Fc|
maps exhibited clear density for residues 235–244 of PAPS reductase in association with
Trx and for the disulfide bond between Cys239 and Cys32. The arrangement of the
interacting protein molecules in the asymmetric unit is physically constrained by the lattice
symmetry and length of the C-terminal peptide. Five cycles of refinement with Buster (30)
were used to complete the initial model (31), which was refined with CNS (32) using tight
restraints on geometry and group B-factors (Table 1). Coordinates and structure factors have
been deposited with the PDB (entry 2O8V). Figures of protein structures and surface area
calculations were generated using PyMOL (33). The Ramachandran plot was computed with
PROCHECK in CCP4 (28).
The model of the sulfite moiety was derived from the refined structure of P. aeruginosa
APS reductase (8), using the sulfite group of the substrate APS to attach it 2.0 Å from the Sγ
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atom of Cys239 in the PAPS reductase structure (for the Sγ–SO3− bond), while maintaining
tetrahedral bond angles. The energy was not minimized, but the geometry was idealized. It
was unnecessary to adjust any atoms of PAPS reductase or Trx.
RESULTS
Trapping the Covalent Trx–PAPS Reductase Intermediate
Our first experimental objective was to devise a strategy that would stabilize the complex
between PAPS reductase and Trx1. Under normal conditions, the predicted protein–protein
intermediate is too fleeting for direct interrogation by biochemical or X-ray crystallography
methods (3). To facilitate its capture, the resolving cysteine at the active center of Trx,
Cys35 (Trx residues italicized), was changed to alanine, which would selectively affect the
breakdown, but not the ability to form the protein–protein intermediate (34) (Figure 2A).
This variant of Trx was added either to the PAPS reductase S-sulfocysteine intermediate
(formed via incubation with PAPS; see Experimental Procedures) or to PAPS reductase
only. Formation of the Trx–PAPS reductase complex was monitored by reversed phase
HPLC (Figure 2B), nonreducing SDS–PAGE (Figure S1 of the Supporting Information),
and size-exclusion chromatography (data not shown). Mass spectrometry analysis of
proteins isolated by reversed phase HPLC confirmed the identities of observed peaks
(Figure 2B). The native molecular mass of the PAPS reductase–Trx complex estimated
using size-exclusion chromatography was ~90 kDa, consistent with homodimeric PAPS
reductase in association with two Trxs. Denaturing analysis of the Trx–PAPS reductase
complex using reversed phase HPLC or SDS–PAGE disrupted the noncovalent interactions
between monomers in the PAPS reductase homodimer. The Trx–PAPS reductase complex,
however, remained covalently associated via the mixed disulfide bond (Figure 2 and Figure
S1); the molecular mass of this species as determined by electrospray mass spectrometry and
mobility via SDS–PAGE was ~45 kDa. Incubation of the protein complex with a chemical
reducing agent, such as DTT, reduced the disulfide bond between Trx and PAPS reductase,
as expected (data not shown).
The PAPS reductase–Trx1 complex formed readily from the S-sulfocysteine intermediate
(Figure 2 and Figure S1). To estimate the apparent dissociation constant (Ki) of Trx
Cys35Ala for the PAPS reductase S-sulfocysteine intermediate (see Experimental
Procedures), the rate of complex formation could be quantified by measuring the change in
peak area for free Trx using HPLC or fluorescence of SYPRO ruby-stained nonreducing
SDS–PAGE gels. The later method exhibited a more sensitive limit of detection and was
therefore used to determine an apparent Ki of 1.1 μM for these species (Figure 2C).
Formation of a covalent complex between P. aeruginosa APS reductase and E. coli Trx
Cys35Ala has been reported in previous biochemical work (35). A high affinity for the S-
sulfated enzyme was observed when P. aeruginosa APS reductase was reacted with the P.
aeruginosa Trx Cys35Ala variant (Figure S2 of the Supporting Information), consistent with
the general mechanism proposed for this family of enzymes. The PAPS reductase–Trx
complex, formed via reaction of the PAPS reductase S-sulfocysteine intermediate with Trx1,
represents a stabilized mixed disulfide intermediate along the reaction pathway and was the
focus of subsequent structural investigation.
Protein–Protein Interaction
The structure of the PAPS reductase–Trx1 complex was determined to 3.0 Å (Table 1). Trx
binds to PAPS reductase at the enzyme surface adjacent to the active site cleft (Figure 3A).
The association of residues 2–220 and 235–244 within the same PAPS reductase molecule is
uniquely defined; all other possible connections between residues 2–220 and symmetry-
related residues 235′–244′ are physically impossible. With the connection of residues 2–220
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and 235–244 established, the linkage of residues 235–244 to Trx is established by the
continuous electron density of the mixed disulfide. Consequently, the unique association of
PAPS reductase and Trx1 is defined by the crystal structure. The protein surfaces are
complementary in shape, and 800 Å2 of solvent accessible surface is buried at the PAPS
reductase–Trx interface; an additional 783 Å2 is buried between Trx and PAPS reductase C-
terminal residues 235–244 (Figure 3B). This segment includes Cys239 in the mixed
disulfide with Cys32. The preceding tail residues (221–234) span above the active site
adjacent to the PAPS reductase–Trx interface but are disordered (Lys220–Leu235 distance
of 13.5 Å). An increase in Trp fluorescence occurs when E. coli PAPS reductase is
incubated with Trx (6). Consistent with these data, Trp221 would experience different
solvent exposure as the C-terminal residues rearrange to bind Trx.
Trx’s α-helix 2 and active site Cys32Gly33Pro34Cys35 loop fit into a depression on PAPS
reductase formed on three sides by α-helix 7 (following strand 6 of the β-sheet, residues
186–198), by residues 199–220 wrapping around the phosphate-binding loop (P-loop) at the
back of the active site, and by PAPS reductase residues 235–244 (hereafter, identified as the
“Cys239 peptide”) (Figure 4A). The segment of residues 199–220 contains an ω-loop (36) at
residues 202–212 involved in specific interactions with Trx. Trp205 hydrogen bonds with
the carbonyl of Glu30, and Asp206 participates in the Lys36–Glu30 salt bridge. PAPS
reductase residues Asp206 and Glu207 are also proximal to Ser2 at the N-terminus of Trx.
Aromatic stacking interactions occur for Tyr201 with Trp205 and for Tyr191 with Trp31.
Hydrophobic contacts include Leu210 with Met37 and Gly33 in the Cys32Gly33Pro34Cys35
loop, and with Leu235. Hence, the protein–protein interface includes specific hydrogen
bonds, and electrostatic, aromatic, and hydrophobic interactions.
Trx–PAPS Reductase Complex Cys239–Peptide Interaction
The PAPS reductase Cys239–peptide interaction clasps the Cys32Gly33Pro34Cys35 loop
from the side opposite the ω-loop (Figure 4A). Reciprocally, the peptide lies in a shallow
groove formed between the 30s loop (Trx residues 28–33) at the protein–protein interface
(Trp31Cys32Gly33Pro34-Cys35; Ala35 in the cocrystal structure) and 70s and 90s loops (Trx
residues 71–77 and 91–96, respectively) (Figure 4B). The chain directions of the 30s, 70s,
and 90s loops are locally antiparallel to the Cys239–peptide. The conformation of the
Cys239–Cys32 bond is (−,+,+,+,−), placing it in the commonly occurring –RHspiral class,
consistent with a 5.93 Å separation between Cα atoms (Figure 4C) (37). The disulfide is
surrounded by hydrophobic residues, including Trp31, Pro34, Ala35 (Cys35), Ile75, and cis-
Pro76, but exposed to solvent in the direction of Cys239. The Cαi–Cβi–Sγi–Sγj, Cαj–Cβj–
Sγj–Sγi, and Cβi–Sγi–Sγj–Cβj dihedral angles (i = Cys32Trx1 and j = Cys239) are 57°, 117°,
and 92°, respectively. The parameters observed for the PAPS reductase–Trx intermolecular
disulfide bond are quite similar to those observed in the BASI–Trx complex (25). In
particular, both disulfide bonds exhibit right-handed geometry and similar dihedral angles
and Cα atom distances.
Cys239–peptide residues 237–242 adopt an extended β-conformation and bridge the 70s and
90s loops to form main chain hydrogen bonds between the Arg237 carbonyl and Ala93
amide, the Cys239 amide and Ile75 carbonyl, and the Leu241 amide and Arg73 carbonyl
(Figure 4B). In this conformation, Leu241 fits into a hydrophobic pocket comprised of Trx
residues Trp31, Ile60, Ala67, Ile72, and Ile75. On its solvent-exposed side, the Cys239-
peptide participates in an interdigitated network of salt bridges that incorporates Arg237,
Glu238, Arg73, and Glu243 (Figure 4B); His242 is within 4.5 Å of Asp186 on the reductase.
Consequently, the Cys239-peptide is fully recognized, with hydrophobic pockets for the
mixed disulfide and Leu241, three main chain hydrogen bonds with Trx, and an interprotein
array of three salt bridges. In accord with this recognition, the glutathione-like sequence,
Glu238Cys239Gly240Leu241His242, is strictly conserved in PAPS reductases, residues
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Lys236, Arg237, and Asp186 are strongly conserved, and Trx residue Arg73 is absolutely
conserved (8).
Quaternary Structure
Both E. coli PAPS reductase and the PAPS reductase–Trx1 complex crystallize as dimers in
space group C2221 with local 2-fold axes superimposed on crystallographic 2-fold axes,
consistent with each being a homodimer in solution (3, 9). The identity of the solution dimer
cannot be deduced from symmetry considerations, because the asymmetric unit contains just
one PAPS reductase–Trx1 complex and because all 2-fold axes are equivalent by the space
group operators. Hence, the most likely dimer can be inferred only by homology. Because
the rmsd between Cα atoms of PAPS reductase subunits is 1.09 Å in the two structures, we
expect that the PAPSr–Trx1 solution dimer resembles that proposed for the PAPS reductase
dimer (9) (Figure S3 of the Supporting Information). In this homodimer, the active sites face
away from each other and the distance between Lys220 residues is ~36 Å (i.e., the C-
terminal tail cannot interact with the opposite subunit), and a total of 790 Å2 of accessible
surface area is buried at the interface. P. aeruginosa APS reductase is also structurally
homologous to E. coli PAPS reductase (8). In this case, the solution homotetramer
crystallizes in a triclinic unit cell with local 222-fold symmetry only. Interestingly, the
proposed PAPS reductase and PAPS reductase–Trx1 homodimers correspond to the AC pair
in the P. aeruginosa APS reductase crystal structure. Thus, a common homodimer interface
is observed in three crystal structures, irrespective of lattice contacts or space group.
DISCUSSION
The protein complex used for these studies was formed via reaction of Trx Cys35Ala with
PAPS reductase S-sulfocysteine intermediate, E-Cys-Sγ-SO3−; the S-sulfocysteine
intermediate has been characterized in previous biochemical and mass spectrometry studies
(3, 8, 21). Since (1) a stable enzyme–S-sulfocysteine intermediate forms upon addition of
sulfonucleotide substrate, (2) reduction of the intermediate, and concomitant production of
sulfite, is Trx-dependent, and (3) biochemical and structural data are not consistent with
disulfide formation between Cys239s in the PAPS reductase homodimer, we have proposed
the mechanism for sulfonucleotide reduction illustrated in Figure 1B (3). Structural
observation of the PAPS reductase C-terminal tail outside of the active site, and in highly
specific interaction with Trx, provides strong support for the central feature of the proposed
mechanism, that formation of S-sulfocysteine is followed in subsequent steps by
nucleophilic attack of Trx Cys32 on the Sγ atom of this intermediate. These structural
findings are further supported by the high-affinity interaction between Trx and S-sulfated
SRs (Figure 2 and Figure S2).
In the cocrystal structure, Trx interacts with the last 10 residues of the PAPS reductase C-
terminal tail, spanning ~20 Å (Figure 4B). Recognition of this segment consists of
hydrophobic contacts, main chain hydrogen bonds, and a network of interprotein salt bridge
interactions. As a consequence of these extensive contacts, Cys32 is exquisitely positioned
for nucleophilic attack at the Cys239 Sγ atom of the S-sulfocysteine, as modeled in Figure 5
from the cocrystal structure. The Cys35 Sγ atom would, in turn, be suitably positioned to
resolve the mixed protein disulfide (distance to the Cys32 Sγ atom of <3 Å based on the
position Ala35). In terms of S-sulfocysteine recognition prior to nucleophilic attack by Trx,
it is interesting to note the formation of a putative sulfite-binding pocket at the protein–
protein interface (Figure 5) by a constellation of strongly conserved residues (8). The pocket
contains a potential hydrogen bond with the Gly33 amide, while the PAPS reductase residue
Asn187 (positioned by Arg157 and Glu159) can hydrogen bond to the carbonyl of Trp31
and the sulfite moiety. Pro34 and Leu235 define the other side of the pocket. In this model,
recognition of S-sulfate can entail hydrogen bonds with two amides, while sulfite release is
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accommodated by access to the solvent. Consistent with the conservation of mechanism, an
analogous sulfite-binding pocket forms at the interface of P. aeruginosa APS reductase
when it is superimposed on the PAPS reductase–Trx structure (8).
In both NFκB and Ref-1 structures, at least nine of 13 residues adopt an extended β-
conformation across the 30s, 70s, and 90s loops of Trx, analogous to the extensive
interactions observed for PAPS reductase. These loop segments in Trx, aptly termed the
“substrate recognition loop motif”, also play a primary role in molecular recognition of
BASI residues in the BASI–Trx complex (25). The chain direction of PAPS reductase and
BASI peptide residues adjacent to the mixed disulfide are antiparallel to Trx substrate
binding loops. However, loop segments in HvTrxh2 interact with only three BASI residues,
Asp146Trp147Cys148 (with Cys148 forming part of the mixed disulfide). One possible
explanation proposed by Maeda et al. for the larger number of residues in Trx–peptide
interactions is that the synthetic NFκB and Ref-1 substrates possess more conformational
freedom, relative to folded BASI protein, and are therefore able to make more contacts.
Consistent with this hypothesis and the mobility of the 25 C-terminal residues of PAPS
reductase, more extensive interactions with Trx are observed in the structure presented here.
Glutaredoxin (Grx) can also act as a protein reductant for E. coli PAPS reductase (38) and
M. tuberculosis APS reductase (K. S. Carroll, unpublished observations). Grxs belong to the
Trx superfamily and share a common fold, including the position of several loop segments
and the active site cysteine residues. In this context, related structures are E. coli Grx-1 in
complex with a peptide fragment derived from ribonucleotide reductase (39) and Grx-1 and
Grx-3 in complex with the tripeptide glutathione, GluCysGly (40, 41). The latter
comparisons are particularly relevant since the C-terminal residues in PAPS reductase
contain an absolutely conserved glutathione-like motif, Glu238Cys239Gly240Leu241-His242.
Recognition of the tripeptide by Grx is largely electrostatic, and in accord with these
observations, hydrogen bonding and salt bridge interactions dominate recognition of C-
terminal peptide residues in PAPS reductase by Trx.
Chemical reductants with redox potentials similar to that of Trx, such as DTT or GSH, do
not efficiently cleave the S-sulfocysteine in the folded enzyme (3, 8). The simplest
interpretation of this observation is that access to the S-sulfate intermediate is restricted, as
C-terminal residues remain closed over the active site. Hence, the S-sulfocysteine moiety
remains sequestered in the active site until the C-terminal residues are displaced through
protein–protein interaction with Trx, the state evidenced in the structure presented here.
Interestingly, conformational rearrangement involving a labile intermediate is also observed
in the cysteine desulfurylase, SufS, a component of the SUF iron–sulfur cluster biosynthetic
system (42, 43). These pyridoxal phosphate-dependent proteins catalyze the conversion of
L-cysteine to L-alanine and sulfane sulfur via a covalent persulfide intermediate (44). The
catalytic cysteine nucleophile resides on a highly mobile loop that transfers a sulfide group
to another protein, such as SufE, without releasing it into solution (45, 46). Hence, a general
strategy for protecting labile, reactive intermediates in sulfur metabolism appears to be to
incorporate mobile structural elements in the enzymes mediating transfer.
With regard to residues and protein–protein contacts that could be critical for mediating
conformational changes in the PAPS reductase C-terminal domain, we consider both the
cocrystal structure presented here and the structure of the E. coli PAPS reductase (PDB
entry 1SUR), crystallized in the absence of substrate and Trx (9) (Figure S3). The final 30
residues in the C-terminus of 1SUR are disordered, and thus, a direct comparison of this
mobile element is not possible. Nonetheless, conformational rearrangements are observed in
two regions adjacent to the active site (and are not involved in crystal contacts). One of the
mobile elements is the Arg loop (Arg157Arg158Glu159Gln160Ser161Gly162Ser163-Arg164)
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between β4 and β5. On the basis of structural similarities of substrate-bound APS reductase,
Arg164 (one of only six absolutely conserved residues in PAPS reductase) is predicted to
contact the oxygen that bridges the substrate phosphorus and sulfur atoms (8). In 1SUR, the
Arg loop is folded over the active site, and in the structure presented here, the Arg loop is
displaced onto the enzyme surface. Additional conformational differences are also observed
in the ω-loop, with Tyr209 and other residues shifting relative to 1SUR. Mutation of Tyr209
to Phe alters the Michaelis constant (Km) of E. coli PAPS reductase with Trx (6), in accord
with its location proximal to the protein–protein interface and to Lys220 in the C-terminal
tail. Taken together, these observations suggest that conformational changes associated with
Trx binding involving residues in the C-terminal tail, the flexible Arg loop (e.g., Leu235 and
Ser161, respectively), and the ω-loop could collectively facilitate displacement of the S-
sulfated C-terminal residues from the active site.
Integrating the cocrystal structure with prior structural and biochemical studies, we can
formulate a model for conformational rearrangement during the SR catalytic cycle (Figure
2A). We hypothesize that binding of the sulfonucleotide substrate favors closure of the C-
terminal residues over the active site. This is a logical step since the C-terminal residues
contain the essential cysteine nucleophile and must come into the proximity of the substrate.
Also consistent with the proposed ordering of these residues, formation of the S-
sulfocysteine intermediate confers proteolytic resistance to the C-terminal tail and Arg loop
(8). Subsequent association of Trx with PAPS reductase adjacent to the active site, and
accompanying conformational rearrangements, displaces the S-sulfated C-terminus from the
active site and is consistent with the state observed in our cocrystal structure. The observed
protein–protein interaction strategically positions Trx to bind the displaced residues and
reduce the S-sulfocysteine intermediate in subsequent steps. Consequently, key steps in the
catalytic cycle, S-sulfocysteine formation and reduction, are delineated by considerable
structural rearrangement in PAPS reductase and take place at distinct sites on the enzyme.
Our structure of Trx with a full-length protein target affords the opportunity to identify
additional sites involved in protein–protein recognition. In this context, our structure reveals
that Trx interacts with PAPS reductase at a second site adjacent to the ω-loop and involves
contacts between Lys36, Glu30, Trp31, and Trp205 and Asp206, all highly conserved
residues (Figure 4A). This observation (and the additional 800 Å2 of buried surface area) is
an important feature that distinguishes the PAPS reductase–Trx complex from previously
reported synthetic peptide fragment- or BASI–Trx complexes. In addition to substrate
reduction, the functional consequences of this interaction (e.g., mediating conformational
rearrangements) are significant for the mechanism of sulfonucleotide reduction and may
represent a common theme among enzymes that require Trx. In addition to the BASI–Trx
complex, only one other structure of Trx in a mixed disulfide with a full-length protein has
been reported. This landmark structure, the complex between Trx and its in vivo reductant
(Trx reductase), was determined to 3.0 Å resolution by Lugwig and co-workers (47). In this
structure, Trx makes multiple contacts with Trx reductase NADPH and FAD nucleotide-
binding domains to promote a large-scale domain rotation that is essential for the transfer of
electrons in this reaction. Trx has also been crystallized in a noncovalent complex with T7
DNA polymerase, an interaction that stabilizes a processive conformation but does not
involve redox chemistry (48). A notable feature of the cocrystal structures in which multiple
Trx–protein interacting sites are observed (e.g., Trx reductase and T7 DNA polymerase) is
the association of Trx with regions of mobility and conformational change, which is
analogous to the situation in the PAPS reductase–Trx complex.
The structure reported here reveals unique interactions between Trx and PAPS reductase
with significant implications for the chemical and conformational aspects of sulfo-
nucleotide reduction. Visualization of the PAPS reductase C-terminal tail outside the active
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site, and in association with Trx, supports the essential feature of the mechanism of
sulfonucleotide reduction, that formation of the S-sulfocysteine intermediate, and its
subsequent reduction, are discrete chemical steps of the overall reaction. Two key states
remaining to be characterized structurally are the PAPS reductase S-sulfocysteine
intermediate in complex with Trx prior to cleavage and the S-sulfated peptide with the
product, PAP, bound in the active site. This structure motivates experiments that target the
observed peptide and protein recognition surfaces as sites for inhibition of sulfonucleotide
reductase activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(A) Depending on the organism, APS or PAPS is reduced to sulfite by APS reductase or
PAPS reductase, respectively. The sulfite product formed in this reaction is further reduced
to sulfide, and the sulfur is incorporated into cysteine. This amino acid is then converted into
numerous metabolites, including methionine and cofactors, such as coenzyme A. (B)
Mechanism proposed for sulfonucleotide reduction.
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Figure 2.
Formation of the PAPS reductase–Trx1 protein complex. (A) Strategy for trapping the E.
coli PAPS reductase–Trx1 protein complex. (B) Complex formation was monitored at 220
nm by reversed phase HPLC analysis and plotted as a function of time. E. coli Trx1
Cys35Ala (10 μM) was incubated with increasing amounts PAPS reductase S-sulfocysteine
intermediate [0 (i), 4 (ii), 9 (iii), and 20 μM (iv) at the left] or PAPS reductase alone [0 (i)
and 20 μM (iv) at the right]. Mass spectrometry analysis of the observed peaks indicated
masses of 13 937.1 Da for Trx1 [(●) 13 937.8 Da, theoretical], 30 007.3 Da for PAPS
reductase [(■) 30 007.5 Da, theoretical], and 43 941.8 Da for the PAPS reductase–Trx1
complex [(*) 43 942.4 Da, theoretical]. (C) Rate of formation of the PAPS reductase–Trx1
complex from the PAPS reductase S-sulfocysteine intermediate (1 μM) plotted as a function
of Trx Cys35Ala concentration, monitored by SYPRO ruby-stained nonreducing SDS–
PAGE gel analysis. The dashed line represents a fit of the data to the equation derived for
active site-directed irreversible inhibitors as described in Experimental Procedures and gave
an apparent Ki value of 1.1 μM for the PAPS reductase S-sulfocysteine intermediate and
Trx1 Cys35Ala.
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Figure 3.
Overall view of the PAPS reductase–Trx1 complex in the cocrystal structure. (A) The
flexible C-terminal tail of the reductase (residues 235–244; all atoms shown) fits into a
groove on Trx1 comprised of the 30s, 70s, and 90s loops (Trx1 residues 28–33, 71–77, 91–
96, respectively; Trx1 residues in italics); the mixed disulfide is formed between Cys239 of
the reductase and Cys32 of Trx. Trx in turn is bound to PAPS reductase among an ω-loop
(residues 202–212, colored yellow), helix α7, and the C-terminal Cys239-peptide (residues
235–244). Residues 221–234 of PAPS reductase are disordered in the cocrystal structure
(indicated by a dashed yellow line in front of the ω-loop). (B) Solvent accessible surface
depiction of the PAPS reductase–Trx1 complex. In panel B and in Figures 4 and 5, PAPS
reductase residues 1–220 are colored green, C-terminal peptide residues 235–244 are
colored yellow, and Trx is colored gray.
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Figure 4.
(A) Specific recognition of PAPS reductase by Trx1 occurs via residues in an ω-loop of the
reductase and the 30s loop of Trx1 and involves hydrogen bonds, aromatic stacking, and
hydrophobic interactions. The view is the same as in Figure 3A. (B) Specific recognition of
the C-terminal peptide of PAPS reductase (yellow) by Trx1 (gray) involves three hydrogen
bonds between main chain atoms, hydrophobic contacts with Leu235 in a pocket on TrxA,
and interdigitation of Arg237, Glu238, Arg73, and Glu243 in a network of three salt bridges.
The view is the same as in Figure 3A. (C) Electron density for the mixed disulfide formed
between PAPS reductase Cys239 and Trx1 Cys32 (σA-weighted 2|Fo| − |Fc| map contoured
at 1.7σ). Density for adjacent residues in the PAPS reductase C-terminal peptide (yellow)
and in the TrxA 30s loop (gray) is also shown. The view is from behind the complex as
shown in Figure 3A (i.e., the Glu238Cys239Gly240 peptide orientation is reversed).
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Figure 5.
Model for the S-sulfocysteine intermediate of PAPS reductase bound to Trx1, based on the
crystal structure of the mixed disulfide complex. The sulfite moiety fits into a pocket at the
PAPS reductase–Trx1 interface. PAPS reductase residues in the C-terminal tail are colored
yellow and other residues green; Trx1 residues are colored gray with labels in italics.
Potential hydrogen bonds (dotted lines; distances in angstroms) include those from Asn187
to the sulfite and the carbonyl of Trp31 and from the amide of Gly33 to the sulfite. The
green arrow represents the nucleophilic attack that must occur for formation of the mixed
disulfide and displacement of sulfite; the distance between the Sγ atoms of Cys239 and
Cys32 in the cocrystal structure is 2.02 Å. The resolving cysteine of Trx, Cys35, is mutated
to Ala in the complex (visible below Pro34 in the 30s loop). With respect to Figure 3A, the
view is approximately from the N-terminus of Trx1 looking along the axis of the C-terminal
peptide.
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Table 1
Crystallographic Statistics
Unit Cell and Data Collection
space group C222(1)
a, b, c (Å) 40.93, 111.15, 153.43
SSRL beamline BL 1-5
wavelength (Å) 0.9794
resolution (Å) 3.00
no. of observations 33575
no. of reflections 7334
redundancy 4.6
completenessa (%) 99.7 (99.6)
〈I〉/〈σI〉a 9.7 (2.1)
Rsymm(I)a 0.126 (0.340)
Refinement
resolution range (Å) 50.0–3.00
no. of reflections >0.0σF 7319
R-factora 0.297 (0.381)
Rfreea (5.0% of data) 0.308 (0.454)
rmsd for bonds (Å) 0.004
rmsd for angles (deg)b 1.24
Model
protein residues 〈B-factor〉 (Å2)
PAPS reductase 2–220, 235–244 56.4
Trx1 1–108 58.5
a
Values for the highest-resolution shell (3.11–3.00 Å) are in parentheses.
b
Ramachandran plot: 79.6% of residues in most favored regions, 18.4% in allowed regions, and 2.0% in generously allowed regions.
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